Jaguar Animal Health (NASDAQ:JAGX) Stock Price Passes Below Fifty Day Moving Average – Here’s What Happened

Jaguar Animal Health, Inc. (NASDAQ:JAGX)’s share price crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $2.65 and traded as low as $0.97. Jaguar Animal Health shares last traded at $1.03, with a volume of 228,810 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on JAGX. Wall Street Zen raised shares of Jaguar Animal Health from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Jaguar Animal Health Stock Down 22.6%

The firm has a market cap of $618,000.00, a PE ratio of -0.00 and a beta of -0.11. The company has a 50-day simple moving average of $2.65 and a two-hundred day simple moving average of $13.47.

Jaguar Animal Health (NASDAQ:JAGX) last announced its quarterly earnings data on Wednesday, May 20th. The biotechnology company reported ($13.60) EPS for the quarter, topping the consensus estimate of ($149.10) by $135.50. The company had revenue of $20.27 million during the quarter, compared to the consensus estimate of $4.21 million.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.